文献速递泌尿生殖技术与安全PETCT

基于PSMA PET器官特异性肿瘤体积的前列腺癌预后风险评分

A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes.
PubMed 文献 · Radiology · 2023-04-18

该回顾性研究纳入1348例前列腺癌患者,利用神经网络自动量化PSMA PET上的器官特异性肿瘤体积,构建并验证了整合总体、骨及内脏肿瘤体积的体重调整预后风险评分,在内部验证队列(C指数0.82)、外部验证队列(0.74)及去势抵抗(0.75)和激素敏感(0.68)患者中均显示良好预测总体生存的能力。

要点

  • PSMA PET可自动量化总体、骨及内脏肿瘤体积,用于构建预后风险评分。
  • 该评分预测总体生存的内部验证C指数为0.82,外部验证为0.74。
  • 在去势抵抗和激素敏感患者中C指数分别为0.75和0.68。

核心结论

  • 基于PSMA PET器官特异性肿瘤体积构建的预后风险评分在内部和外部验证队列中均对总体生存显示良好的模型拟合。

研究设计与样本

  • 中心A患者分为训练队列(918例,80%)和内部验证队列(230例,20%),中心B随机选取200例作为外部验证队列。
  • 器官特异性肿瘤体积由神经网络从PSMA PET扫描中自动量化。
  • 采用多变量Cox回归并以AIC为指导选择预后评分,训练集拟合的最终评分应用于两个验证队列。

诊断标准与关键数值

  • 体重调整的预后风险评分整合总体、骨和内脏肿瘤体积,内部验证C指数0.82,外部验证0.74。
  • 在去势抵抗患者中C指数0.75,在激素敏感患者中0.68。
  • 与仅含总体肿瘤体积的模型相比,预后评分模型拟合更优(AIC 3324 vs 3351;似然比检验P < .001)。
  • 校准图显示模型拟合良好。

临床应用与阅片要点

  • 可将PSMA PET自动量化的总体、骨及内脏肿瘤体积整合为体重调整风险评分,辅助个体化总体生存预估。

局限性

  • 回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Prostate-specific membrane antigen (PSMA) PET has high specificity in localizing primary tumors and metastases in patients with prostate cancer, but the individual overall survival probability is still difficult to estimate. Purpose To develop a prognostic risk score using PSMA PET-derived organ-specific total tumor volumes for predicting overall survival in patients with prostate cancer. Materials and Methods Men with prostate cancer who underwent PSMA PET/CT from January 2014 to December 2018 were evaluated retrospectively. All patients from center A were split into training (80%) and internal validation (20%) cohorts. Randomly selected patients from center B were used for external validation. Organ-specific tumor volumes were automatically quantified from PSMA PET scans by a neural network. A prognostic score was selected using multivariable Cox regression guided by the Akaike information criterion (AIC). The final prognostic risk score fitted on the training set was applied to both validation cohorts. Results A total of 1348 men (mean age, 70 years ± 8 [SD]) were included, with 918 patients in the training cohort, 230 in the internal validation cohort, and 200 in the external validation cohort. The median follow-up time was 55.7 months (IQR, 46.7-65.1 months; >4 years; 429 deaths occurred). A body weight-adjusted prognostic risk score integrating total, bone, and visceral tumor volumes obtained high C index values in the internal (0.82) and external (0.74) validation cohorts, as well as in patients with castration-resistant (0.75) and hormone-sensitive (0.68) disease. The fit of the statistical model for the prognostic score was improved compared with a model containing total tumor volume only (AIC, 3324 vs 3351; likelihood ratio test, P < .001). Calibration plots ascertained good model fit. Conclusion The newly developed risk score that included prostate-specific membrane antigen PET-derived organ-specific tumor volumes had good model fit for predicting overall survival in both internal and external validation cohorts. Published under a CC BY 4.0 license. Supplemental material is available for this article. See also the editorial by Civelek in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Seifert, Rasul, Seifert, et al. A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes. Radiology. 2023. PMID: 37070991. doi:10.1148/radiol.222010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。